1. Home
  2. ADAG vs EVF Comparison

ADAG vs EVF Comparison

Compare ADAG & EVF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$4.22

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$4.98

Market Cap

90.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
EVF
Founded
2011
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
260.3M
90.3M
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
ADAG
EVF
Price
$4.22
$4.98
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.25
N/A
AVG Volume (30 Days)
218.8K
52.2K
Earning Date
04-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$4.85
52 Week High
$4.75
$5.75

Technical Indicators

Market Signals
Indicator
ADAG
EVF
Relative Strength Index (RSI) 62.22 49.67
Support Level $3.21 $4.92
Resistance Level $4.66 $5.02
Average True Range (ATR) 0.37 0.04
MACD 0.08 0.00
Stochastic Oscillator 80.57 40.61

Price Performance

Historical Comparison
ADAG
EVF

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

Share on Social Networks: